Is OMCL or OPRX more undervalued in 2026?

CirclFi compares Omnicell, Inc. (OMCL) and OptimizeRx Corporation (OPRX) using 13 institutional-grade valuation models. OMCL has a Quality of Company score of 8.0/10 while OPRX scores 9.3/10.

Which is a better buy — OMCL or OPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OMCL and OPRX valuations compare?

OMCL at $44.72 and OPRX at $5.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OMCL vs OPRX Valuation Comparison 2026 — Intrinsic Value Analysis

OMCL

Health Information Services

Omnicell, Inc.

Quality

8.0

out of 10

Value Trap

LOW

Price

$44.72

Last close

Models

13/13

Active

OPRX

Health Information Services

OptimizeRx Corporation

Quality

9.3

out of 10

Value Trap

LOW

Price

$5.10

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	OMCL Fair Value	OMCL Upside	OPRX Fair Value	OPRX Upside
Bayesian DCF	Intrinsic	$37.74	-15.6%	$8.30	+62.8%
Earnings Power Value	Intrinsic	$8.73	-80.5%	$6.98	+36.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OMCL vs OPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OMCL vs OPRX — Which Stock Is More Undervalued?

OPRX scores higher with a 9.3/10 quality rating vs OMCL's 8.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Omnicell, Inc. (OMCL) and OptimizeRx Corporation (OPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OMCL currently trades at $44.72 with a QOC of 8.0/10, while OPRX trades at $5.10 with a QOC of 9.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).